(Q45398766)

14 December 2017

title

Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection (English)

1 reference

14 December 2017

1 reference

Aimi Kanada

1

1 reference

14 December 2017

Tetsuo Takehara

2

1 reference

14 December 2017

Kazuyoshi Ohkawa

3

1 reference

14 December 2017

Michio Kato

4

1 reference

14 December 2017

Tomohide Tatsumi

5

1 reference

14 December 2017

Takuya Miyagi

6

1 reference

14 December 2017

Ryotaro Sakamori

7

1 reference

14 December 2017

Shinjiro Yamaguchi

8

1 reference

14 December 2017

Akio Uemura

9

1 reference

14 December 2017

Keisuke Kohga

10

1 reference

14 December 2017

Akira Sasakawa

11

1 reference

14 December 2017

Hayato Hikita

12

1 reference

14 December 2017

Kiyomi Kawamura

13

1 reference

14 December 2017

Tatsuya Kanto

14

1 reference

14 December 2017

Naoki Hiramatsu

15

1 reference

14 December 2017

Norio Hayashi

16

1 reference

14 December 2017

publication date

9 December 2007

1 reference

14 December 2017

1 reference

14 December 2017

volume

38

1 reference

14 December 2017

issue

6

1 reference

14 December 2017

page(s)

622-628

1 reference

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00307.X

10.1111/J.1872-034X.2007.00307.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference